当归饮子加减联合盐酸奥洛他定治疗慢性荨麻疹的临床效果

Clinical Effect of Modified Danggui Yinzi Combined with Olopatadine Hydrochloride in the Treatment of Chronic Urticaria

目的:探讨慢性荨麻疹(CU)患者应用当归饮子加减联合盐酸奥洛他定治疗的效果。方法:采用随机数字表法将2021年1月—2023年1月贵溪市中医院收治的60例CU患者分为两组,各30例。两组均给予盐酸奥洛他定片治疗,观察组加用当归饮子加减治疗,两组均连续治疗4周。对比两组治疗效果、症状及体征评分、血清学指标、CU活动性和生活质量、不良反应发生率及复发率。结果:观察组治疗后白介素-2(IL-2)、γ干扰素(IFN-γ)水平均较对照组高,症状及体征评分、皮肤病生活质量指数(DLQI)评分、荨麻疹活动性评分(UAS)、白介素-4(IL-4)、免疫球蛋白E(IgE)水平均较对照组低,差异均有统计学意义(P<0.05);观察组总有效率较对照组高,复发率较对照组低,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:CU患者应用当归饮子加减联合盐酸奥洛他定治疗可改善临床症状,减少复发,提高生活质量,调节免疫相关因子,且安全性好。

Objective:To investigate the effect of modified Danggui Yinzi combined with Olopatadine Hydrochloride in the treatment of patients with chronic urticaria(CU).Method:A total of 60 patients with CU admitted to Guixi Traditional Chinese Medicine Hospital from January 2021 to January 2023 were divided into two groups by random number table method,with 30 cases in each group.Both groups were treated with Olopatadine Hydrochloride Tablets,and the observation group was add modified Danggui Yinzi for treatment.Both groups were treated continuously for 4 weeks.The treatment effect,symptom and sign scores,serological indexes,CU activity and quality of life,incidence of adverse reaction and recurrence rate were compared between the two groups.Result:After treatment,the levels of interleukin-2(IL-2)and interferon-γ(IFN-γ)in the observation group were higher than those in the control group,and the symptom and sign scores,dermatology life quality index(DLQI)scores,urticaria activity score(UAS)and the levels of interleukin-4(IL-4)and immunoglobulin E(IgE)were lower than those in the control group,the differences were statistically significant(P<0.05).The total effective rate of the observation group was higher than that of the control group,and the recurrence rate was lower than that of the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The application of modified Danggui Yinzi combined with Olopatadine Hydrochloride in the treatment of patients with CU can improve the clinical symptoms and signs,reduce the recurrence,improve the quality of life,regulate immune-related factors,and have good safety.